TheraKine has achieved both significant fundraising and medical milestones since its creation in 2004. TheraKine has combined equity investors, capital from its founders and seed funding with in-kind contributions from leading research and clinical organizations. Those medical milestones include: animal trials for EpiKine™ and laboratory demonstrations of the sustained release delivery systems for OptiKine™ and AngioKine™.
TheraKine’s progress to date, and its highly efficient on-going clinical programs are supported by:
- Private seed round investors with extensive experience in medical discovery and biologics’ development and commercialization.
- Coker Capital Partners LLC-A boutique private equity investment firm focused on early stage ventures within the life sciences, technology and other diversified sectors. Coker Capital is the investment management arm of The Coker Group, one of the most respected healthcare management consultancies in the U.S.
-
In kind support has been provided by a number of distinguished US and European research centers. The next round of funding will be used to expand international and domestic patents, hasten the developments of the three products, complete the necessary pre-clinical and clinical trials, and then move into human clinical trials.
For further information on TheraKine, please contact:
Jerry Seelig
(310) 841-2549
jseelig@therakine.com
TheraKine Ltd.
58 Edgewood Avenue
Suite 114
Atlanta, Georgia 30303